Performance and Safety Evaluation of the FHK®-CK Knee Prosthesis Indicated for the Treatment of Primary and Secondary First Line Gonarthrosis and Revision Arthroplasty - 2 Years Follow-up - A Pilot Study
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Total Knee Arthroplasty
- Sponsor
- FH ORTHO
- Enrollment
- 92
- Locations
- 7
- Primary Endpoint
- Functional performance
- Status
- Recruiting
- Last Updated
- 10 months ago
Overview
Brief Summary
The life expectancy worldwide is increasing and leading to an increase of knee arthroplasty. Also, as millions of people around the world are currently living with a Total Knee Arthroplasty (TKA), the need for revision surgery represents a large public health burden. In this context, FH ORTHO company develops FHK®-CK (prosthesis + ancillary equipment) which is a knee prosthesis for complex first intention and revision knee arthroplasty. This new medical device complements the FHK® standard first-line range (CE marked).
The FHK®-CK ancillary equipment were designed by expert knee surgeons and is simple, reliable and reproducible. It allows for maximum versatility while remaining compact.
By completing the FHK® range of first intention prostheses, the FHK®-CK allows the surgeon to be on the same level as the competitors by having a first intention and semi-constrained prosthesis. This prosthetic arsenal allows the surgeon to opt for the best solution for his patient so that he can regain mobility and a satisfactory quality of life. Also, in case of failure of the FHK® first-line prosthesis, it will provide the surgeon and the patient with a simple alternative to prosthesis replacement. As it has been developed in line with the first intention, inter-compatibility between the two systems is possible, which simplifies the surgical procedure and reduces the risks for the patient.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Patient requiring knee arthroplasty for primary or secondary gonarthrosis:
- •\* For primary intention arthroplasty: Patient with either
- •major axial deviation,
- •major peripheral failure or
- •bone defect;
- •\* For prosthesis revision surgery: Patient who have had a failed 1st implantation, with or without bone defects.
- •Patient able to understand and answer the questionnaires provided by the protocol;
- •Subject affiliated to a health insurance system or is a beneficiary;
- •Signed informed consent form (ICF) for participation to the research.
Exclusion Criteria
- •Patient with an ongoing acute infection, outside knee to be operated;
- •Patient with a mental or neuromuscular disorder that would create an unacceptable risk of prosthetic instability, prosthetic fixation failure or post-operative complications;
- •Patient with a known allergy to any of the components of the FHK®-CK implants (Nickel, Cobalt, Chromium);
- •Patient with a dependency (drug, alcohol,...) that could affect his/ her ability to comply with the protocol, at the investigator's discretion;
- •Patient requiring knee reconstruction;
- •Patient with any medically significant findings or significant history that may impact the safety, interpretation of results, and/ or participation of the subject in the clinical trial, as determined by the investigator;
- •Patient with an existing knee or hip prosthesis (outside knee to be operated) that may impact the evaluation of the FHK®-CK prosthesis;
- •Patient concurrently participating in another clinical trial or who has recently participated in another clinical trial for which the exclusion period has not been completed.
- •Vulnerable subjects :
- •Pregnant, parturient, or breastfeeding women,
Outcomes
Primary Outcomes
Functional performance
Time Frame: Baseline (preoperatively), at 6 weeks, 6 months, 12 months and 24 months after surgery.
Evolution of the functional performance of FHK®-CK prosthesis using the KSS scoring system, which is composed of 2 sections : Knee score (KSKS) and function score (KSFS). Each section is scored on a scale of 0 to 100 ; the higher the score, the better the overall functionality of the knee. The functional performance of the FHK®-CK prosthesis will be demonstrated at 2 years if an improvement of the KSKS and KSFS scores at least equal to the Minimal Clinically Important Difference (MCID) values is observed.
Secondary Outcomes
- Adverse and serious adverse events evaluation(Through study completion, an average of 2 years)
- Revision rate evaluation(At 6 weeks, 6 months, 12 months and 24 months after surgery.)
- Evaluation of patient's tolerance of the FHK-CK prosthesis(At 6 weeks, 6 months, 12 months and 24 months after surgery.)
- Quality of life assessment(Baseline (preoperatively), at 6 months, 12 months and 24 months after surgery.)
- Device deficiencies evaluation(Through study completion, an average of 2 years)
- Patient's satisfaction about FHK®-CK prosthesis(At 6 months, 12 months and 24 months after surgery)
- Surgeon's satisfaction about FHK®-CK equipment(During surgery)